Where Next For Sesen Bio’s Bladder Cancer Therapy Vicineum?
First-Mover Hopes Dashed By CRL
Executive Summary
A complete response letter from the FDA has dashed Sesen Bio’s hopes of being first with a therapy for treating BCG-unresponsive non-muscle invasive bladder cancer. Its CEO says the FDA’s move may reflect heightened ‘pressure’ regulator is under.
You may also be interested in...
Carisma Takes Its CAR-M Approach In Solid Tumors Public Via Sesen Merger
Merging with the shell of troubled cancer biotech Sesen, Carisma believes its chimeric antigen-receptor-macrophage (CAR-M) platform can bring the immunotherapy application to solid tumors.
Sesen Bio Looks To Partner Vicineum To Save Money As It Mulls Future Strategy
The company, after revealing in May that it was evaluating various partnership or buyout strategies, also said it would sell its IL-6 programs to Roche as it pauses Vicineum’s US development.
Finance Watch: Bausch + Lomb Completes Split From Bausch Health Via IPO
Public Company Edition: Bausch remains the majority shareholder, but B+L is a separate operating company. Also, Rezolute raises $130m in dual financings and BridgeBio outlines job cuts and will out-license assets to conserve cash.